scientific presentations

Phase 2 study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma
Adobe PDF
ASCO 2021, June 2021


Phase 2 Study of MGTA-145 + Plerixafor for Rapid and Reliable Hematopoietic Stem Cell (HSC) Mobilization for Autologous Stem Cell Transplant in Multiple Myeloma (Abstract EP1224)
Adobe PDFEHA Congress 2021, June 2021


MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant
Adobe PDFEBMT 2021 Annual Meeting Presentation, March 2021


MGTA-145, in Combination with Plerixafor in a Phase 1 Clinical Study, Mobilizes Large Numbers of Hematopoietic Stem Cells and a Graft with Potent Immunosuppressive Properties for Autologous and Allogeneic Transplant (Oral Abstract, #35)
Adobe PDFTCT Annual Meeting Presentation, February 2021


MGTA-145 / Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells (Oral Abstract, #16)
Adobe PDFTCT Annual Meeting Presentation, February 2021


MGTA-145/Plerixafor-Mediated HSC Mobilization and Intravenous HDAd5/35++ Vector Injection into Mice Allows for Efficient in vivo HSC Transduction and Stable Gene Marking in Peripheral Blood Cells of CD46-Transgenic and Thalassemia Mice (Abstract #2602)
Adobe PDFASH Annual Meeting Poster, December 2020


MGTA-145, In Combination with Plerixafor in a Phase 1 Clinical Trial, Mobilizes Large Numbers of Human Hematopoietic Stem Cells and a Graft with Immunosuppressive Effects for Allogeneic Transplant (Oral Abstract #184)
Adobe PDFASH Annual Meeting Presentation, December 2020


Rapid and Robust Mobilization of CD34+ HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #A325)
Adobe PDFEBMT Annual Meeting Poster, Aug/Sept 2020


MGTA-145, in Combination with Plerixafor, Rapidly Mobilizes Large Numbers of HSCs in Humans That Can Be Gene Edited with CRISPR/Cas9 and Mediate Superior Engraftment to Standard-of-Care (Abstract #123)
Adobe PDFASGCT Annual Meeting Presentation, May 2020


MGTA-145/Plerixafor-Mediated HSC Mobilization Allows for Efficient In Vivo HSC Transduction and Stable Gene Marking in Murine Peripheral Blood Cells (Abstract #810)
Adobe PDFASGCT Annual Meeting Poster, May 2020


Phase 1 Clinical Study of MGTA-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF (Abstract #73)
Adobe PDFTCT Annual Meeting Presentation, February 2020


Rapid and Robust Mobilization of CD34 + HSCs without G-CSF Following Administration of MGTA-145 Alone or in Combination with Plerixafor (Abstract #1961)

A Novel Short Half-life Anti-Human CD117-Amanitin ADC Exhibits Dual HSCT Conditioning and Anti-Leukemia Activity and Extends Survival in Multiple Preclinical Models of AML
Adobe PDFEBMT Annual Meeting Poster, March 2021


A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Pre-clinical Models of Acute Myeloid Leukemia (AML) (Oral Abstract, #53)
Adobe PDFTCT Annual Meeting Presentation, February 2021


A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemia Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML) (Abstract #1044)
Adobe PDFASH Annual Meeting Poster, December 2020


A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #5)
Adobe PDFTCT Annual Meeting Presentation, February 2020


A Non-Genotoxic Anti-CD117 Antibody Drug Conjugate (ADC) Designed for Patient Conditioning Prior to Stem Cell Transplant and HSC-Based Gene Therapy Has a Broad Therapeutic Window Across Species (Abstract #44)
Adobe PDFTCT Annual Meeting Presentation, February 2020


A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem Cell Based Gene Therapy in Nonhuman Primates (Abstract #610)

Targeted CD45 Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model as a Single Agent (Poster #242)
Adobe PDFTCT Annual Meeting Presentation, February 2021


Reversing clonal hematopoiesis and associated atherosclerotic disease by targeted antibody-drug-conjugate (ADC) conditioning and transplant (Abstract #1843)
Adobe PDFASH Annual Meeting Presentation, December 2020


Single Agent CD45-targeted Antibody Drug Conjugate Enables Full Mismatch Allogeneic Hematopoietic Stem Cell Transplantation in a Murine HSCT Model (Abstract #2330)
Adobe PDFASH Annual Meeting Presentation, December 2020


A Novel Targeted Approach to Achieve Immune System Reset: CD45-Targeted Antibody Drug Conjugates Ameliorate Disease in Preclinical Autoimmune Disease Models and Enable Auto HSCT (Abstract #0030)
Adobe PDFEBMT Annual Meeting Poster, Aug/Sept 2020


A CD45-targeted Antibody Drug Conjugate Enables Allogeneic Hematopoietic Stem Cell Transplantation as a Single Agent in Mice (Abstract #A174)
Adobe PDFEBMT Annual Meeting Poster, Aug/Sept 2020


A Novel Targeted Approach to Achieve Immune System Reset: A Single Dose of Magenta CD45-Targeted Antibody Drug Conjugate Enables Autologous HSCT and Ameliorates Disease in Murine Models of Autoimmune Disease (Abstract #3208)
Adobe PDFASH Annual Meeting Poster, December 2019


Administration of a CD45 Antibody Drug Conjugate As a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease (Abstract #120)

Expansion with E478 Significantly Increases the Rate of CRISPR-Mediated Homology Directed Repair (HDR) and Improves Engraftment of Human Hematopoietic Stem Cells (Abstract #10)
Adobe PDFASGCT Annual Meeting Presentation, May 2020

Privacy Preference Center

Advertising

The NID and IDE cookies are set by DoubleClick (which is owned by Google) to help build a profile of your interests and show you relevant ads on other sites. The 1P_JAR cookie (from google.com) carries out information about how the end user uses the website and any advertising that the end user may have seen before visiting the said website.

NID, IDE, 1P_JAR

Analytics

Magenta TX uses these cookies to collect information about how visitors use our Site. We use the information to compile reports and to help us improve the Site. The cookies collect information in an anonymous form, including the number of visitors to the Site, where visitors have come to the Site from and the pages they visited. If you do not allow these cookies we will not be able to include your visit in our statistics. You can read the full Google Analytics privacy policy at: https://www.google.com/policies/privacy/.

_ga,_gat,_gid, _gali

Other

Functionality

The OGPC cookie enables the functionality of Google Maps. s_cc Adobe Site Catalyst cookie, determines whether cookies are enabled in the browser. The s_sq and s_vi, Adobe Site Catalyst cookie, stores information about the previous link clicked within the site as well as identify unique visitors, with an ID and timestamp.

OGPC, s_cc, s_sq, s_vi